Bhisey R A, Veturkar P L
Genotoxicity Unit, Cancer Research Institute, Bombay, India.
Cancer Lett. 1990 Jun 30;52(1):63-9. doi: 10.1016/0304-3835(90)90078-c.
Susceptibility of hairless inbred S/RV Cri-ba or Bare mice to skin tumor development with suboptimal doses of 7,12-dimethylbenz[a]anthracene (DMBA), DMBA-TPA two stage protocol and two stage promotion using 12-O-tetradecanoylphorbol-13-acetate (TPA) as sub-stage 1 promoter and mezerein (MEZ) or phorbol retinoate acetate (PRA) as substage 2 promoter was determined. A single application of 40 or 20 nmol DMBA induced 4-5 papillomas per mouse 40 weeks after initiation while no tumors appeared after similar treatment with 10 or 4 nmol DMBA. Dose response studies for DMBA initiation revealed that 10 nmol DMBA dose saturated the sites for initiation in the resting epidermis. In two stage promotion experiments, MEZ was found to be a potent stage 2 promoter, while PRA acted as a weak complete promoter.
研究了无毛近交系S/RV Cri-ba或裸鼠对次优剂量的7,12-二甲基苯并[a]蒽(DMBA)、DMBA-TPA两阶段方案以及以12-O-十四酰佛波醇-13-乙酸酯(TPA)作为第一阶段启动剂和芫花酯(MEZ)或佛波醇视黄酸乙酸酯(PRA)作为第二阶段启动剂的两阶段促进作用诱导皮肤肿瘤发生的易感性。单次应用40或20 nmol DMBA在启动后40周每只小鼠诱导产生4-5个乳头状瘤,而用10或4 nmol DMBA进行类似处理后未出现肿瘤。DMBA启动的剂量反应研究表明,10 nmol DMBA剂量使静止表皮中的启动位点饱和。在两阶段促进实验中,发现MEZ是一种有效的第二阶段启动剂,而PRA作为一种弱的完全启动剂起作用。